Abstract | BACKGROUND: METHODS: Eight patients with SchS were included in this prospective, single-center, open-label study. After a 3-week baseline, patients received a subcutaneous loading dose of rilonacept 320 mg followed by weekly subcutaneous doses of 160 mg for up to 1 year. Efficacy was determined by patient-based daily health assessment forms, physician's global assessment ( PGA), and measurement of inflammatory markers including C-reactive protein (CRP), serum amyloid A (SAA), and S100 calcium-binding protein A12 ( S100A12). RESULTS: Treatment with rilonacept resulted in a rapid clinical response as demonstrated by significant reductions in daily health assessment scores and PGA scores compared with baseline levels (P < 0.05). These effects, which were accompanied by reductions in CRP and SAA, continued over the treatment duration. Rilonacept treatment was well tolerated. There were no treatment-related severe adverse events and no clinically significant changes in laboratory safety parameters. CONCLUSION:
Rilonacept was effective and well tolerated in patients with SchS and may represent a promising potential therapeutic option.
|
Authors | K Krause, K Weller, R Stefaniak, H Wittkowski, S Altrichter, F Siebenhaar, T Zuberbier, M Maurer |
Journal | Allergy
(Allergy)
Vol. 67
Issue 7
Pg. 943-50
(Jul 2012)
ISSN: 1398-9995 [Electronic] Denmark |
PMID | 22583335
(Publication Type: Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't)
|
Copyright | © 2012 John Wiley & Sons A/S. |
Chemical References |
- Biomarkers
- Inflammation Mediators
- Interleukin-1
- Recombinant Fusion Proteins
- rilonacept
|
Topics |
- Aged
- Biomarkers
(metabolism)
- Female
- Humans
- Inflammation Mediators
(metabolism)
- Interleukin-1
(antagonists & inhibitors)
- Male
- Middle Aged
- Recombinant Fusion Proteins
(adverse effects, therapeutic use)
- Schnitzler Syndrome
(drug therapy, metabolism, pathology)
- Treatment Outcome
- Urticaria
(drug therapy, pathology)
|